

Improving Quality Outcomes with Hospital Information Systems: Can Canadians do it Better?

> Jeremy Theal, MD FRCPC CMIO, North York General Hospital Physician Lead, Ministry of Health HIS Adoption/Benefits Team September 29, 2017

Objectives

- Illustrate examples of improved patient, clinician and financial outcomes possible when implementing advanced hospital information systems in a Canadian environment
- 2. Identify key success factors / lessons learned
- 3. Outline challenges and opportunities unique to Canada



Making a World of Difference

Environmental Scan: What Problems must we Solve?

- **Patients** deserve and demand better quality and safety of inpatient care:
 - 9,250 to 23,750 preventable deaths per year in Canadian hospitals

Baker GR, Norton PG. Canadian Adverse Events Study. CMAJ 2004 170(11): 1678-86

Government must reduce healthcare costs, evidence-based care is expected,
 requirements for hospitals to report detailed outcome/cost data for funding

Excellent Care for All Act, Legislative Assembly of Ontario 2010 Quality-Based Procedures, MOHLTC, Ontario 2012

 Healthcare providers have too much information to process, and need assistance to synthesize data for improved clinical decision-making (traditionally: evidence takes 17 years from publication to bedside)

Kawamoto K et al. Systematic review of clinical decision support system success factors. BMJ 2005


Hospital workflows are often inefficient, and sometimes unsafe

Could electronic systems help to bend the cost/quality curve, providing higher quality and safety at a lower total cost?



Surveying the Landscape: HIT Outcomes

Evaluations Of Outcome Measures Of Health Information Technology, By Type And Rating



Thanks to: Lee Fairclough, HQO

Source: The Benefits Of Health Information Technology: A Review Of The Recent Literature Shows Predominantly Positive Results Melinda Beeuwkes Buntin, Matthew F. Burke, Michael C. Hoaglin, and David Blumenthal Health Aff March 2011 30:3464-471; doi:10.1377/hlthaff.2011.0178



Making a World of Difference

This Isn't Easy

- Unexpected Increased Mortality after Implementation of a Commercially Sold CPOE System
 - Mortality rate increased from 2.8% to 6.57% (OR 3.28)

Han Y et al Pediatrics 2005; 116: 1506-1512

- Lessons Learned <u>Clinician/Informatics Leadership Lacking</u>
 - Insufficient analysis and redesign of clinical workflows
 - No CPOE Order Sets / Clinical Standardization before go-live
 - Insufficient real-world usability testing prior to go-live
 - "One must avoid the temptation to blame the adverse effects on the particular system used. This would be equivalent to stating that a particular brand of tool from a hardware store was unsafe because an injury occurred while someone was misusing it."

Sittig, D et al Pediatrics 2006; 118: 797-801



Making a World of Difference



How We Did It: The North York Story



Making a World of Difference

Community academic hospital affiliated with the University of Toronto



NORTH YORK GENERAL

Catchment area: > 400,000

Three Sites: General, Branson, Seniors' Health

Beds: 426 acute care 192 long-term care

Volumes per year:
124,000 ED visits
31,000 inpatient cases
214,000 outpatient cases
5,800 births





What is eCare?

Advanced EMR with CPOE and electronic documentation

+

Standardization on Evidence-Based Care

÷

Safe Prescribing and e-Medication Management + Clinical Decision Support (Static and Dynamic)



Kickoff: **2007**

Phased Implementation: 2008-2015

Hospital-wide: 2015



Making a World of Difference

Goals of the eCare Project



- Implement advanced EMR to *improve patient outcomes:*
 - Quality and safety of patient care
 - Enable Clinical & Business Intelligence for better decisions
- Embrace culture of standardized, evidence-based care
 Build evidence and best practice into optimized workflows
 Make it "easy to do the right thing"
- SHARED VISION = "by clinicians, for clinicians"
 - > 100% clinician adoption via comprehensive engagement
 - Team-based interprofessional approach/workflows

The Importance of Clinician Review

Details for a Medical Imaging Order:

BEFORE:

Reason for exam (mandatory)

Is patient on oxygen? (mandatory)

Is patient pregnant? (mandatory)

Transport method? (mandatory)

Hospital site? (mandatory)

Order priority? (mandatory)

AFTER:

Reason for exam (mandatory)

Order priority (mandatory)









HIS Adoption and Benefits Team

The Importance of Clinician ReviewBEFORE:AFTER – simpler, safer:

Antibacterial Agents: Inpatient, Suspected Pseudomonas Regimens 🧧 📀

- (a) Combination agent regimen: (Piperacillin-tazobactam, cefepime, imipenem-cilastatin, or meropenem) + (ciprofloxacin or levofloxacin)
- Combination agent regimen: (Piperacillin-tazobactam, cefepime, imipenem-cilastatin, or meropenem) +
 (gentamicin, tobramycin, or amikacin) + (azithromycin, levofloxacin, or moxifloxacin)

piperacillin-tazobactam 🛛 📑 🔻

4.5 gram intravenously every 6 hours

cefepime 📑 🔻

2 gram intravenously every 8 hours

imipenem-cilastatin 🛛 📑 🔻

500 milligram intravenously every 6 hours

meropenem 📑 🔻

1 gram intravenously every 8 hours

ciprofloxacin 🛛 📑 🔻

400 milligram intravenously every 8 hours

750 milligram orally every 12 hours

levoFLOXacin 🛛 📑 🔻

750 milligram intravenously every 24 hours

750 milligram orally every 24 hours

gentamicin 📑 🔻

1.7 milligram/kilogram intravenously every 8 hours

7 milligram/kilogram intravenously every 24 hours

tobramycin 📑 🔻

1.7 milligram/kilogram intravenously every 8 hours

7 milligram/kilogram intravenously every 24 hours

amikacin 📑 🔻

7.5 milligram/kilogram intravenously every 12 hours

15 milligram/kilogram intravenously every 24 hours

azithromycin 🛛 📑 🔻

First-line treatment for SUSPECTED/PROVEN P.AERUGINOSA: piperacillin-tazobactam +/- azithromycin (NYGH)

(a) For patient with true beta-lactam allergy: Meropenem +/- azithromycin. Meropenem is associated with low cross-reactivity among those with a beta-lactam allergy. However, if a true anaphylactic, Ig-E mediated reaction has been documented with beta-lactam exposure, consider Infectious Disease and/or Allergy consultation

Tazocin inj

Suspected Pseudomonas

- 1,500 mg Inj IV q8h NOW
- 3,375 mg Inj IV q8h NOW Instructions: Suggested dose for creatinine clearance 20-40 mL per min.
- 3,375 mg Inj IV q12h NOW Instructions: Suggested dose for creatinine clearance < 20 mL per min.</p>

Zithromax inj 👩

500 mg Inj IV q24h-ATC Duration: 5 days NOW

Merrem inj 💿

- 1000 mg Inj IV q8h NOW Instructions: RESTRICTED TO ID AND INTENSIVISTS
- 1000 mg Inj IV q12hr NOW Instructions: RESTRICTED TO ID AND INTENSIVISTS. Sugested dose for creatinine clearance 10-24 mL/min
- 1000 mg Inj IV q24h-ATC NOW Instructions: RESTRICTED TO ID AND INTENSIVISTS. Sugested dose for creatinine clearance < 10 mL/min</p>





EVIDENCE-BASED CARE: THE GAPS

- 1) Belief Gap: "I know everything already"
- 2) Capacity Gap:

200 MB capacity



6,000 articles/day 300,000 RCT's/year

- Finish medical school and residency knowing everything
- Read and retain 2 articles every single night
- At the end of 1 year:




- 3) Temporal Gap:
 - Average of 17 years for evidence to reach the bedside



Evidence Utilization by Physicians

- "Pull model": almost 0% success rate
- "Push model": 75% success rate



Predictor of Success	Adjusted OR
Computer-based generation of decision support	6.3
Provision of recommendation rather than just an assessment	7.1
Provision of decision support at the time and location of decision-making	15.4
Automatic provision of decision support as part of workflow	112.1

Kawamoto K et al. Systematic review of clinical decision support system success factors. BMJ 2005



Evidence-Based Electronic Order Sets

The KEY catalyst to transform practice with CPOE!

- Standardization of care (e.g. condition-based)
- Current evidence and best practice can be built into clinician workflow
- Enables rapid content updates, real-time decision support
- Encourages an interprofessional approach:
 - Order sets with multi-disciplinary orders
 - Care pathways with key interventions and goals











Pneumonia Admission Order Set: Integrated Evidence

Risk Stratification (home / ward / Critical Care):

Pneumon	ia: CAP - Admission to Medicine (Adult) (Initiated Pending)			
⊿ Admis	ssion/Transfer			
3	SEE LINK for "Quality Based Procedures Clinical Handbook for Community"	y-Acquired Pneumonia" (November 2013)		
	Optimize the second	validated clinical prediction scores		
1	🙀 🛛 🗳 SEE LINK for CRB-65 / CURB-65 Severity Scores for Community-Acquired Pneumonia (CAP)			
3	Please refer to CrCU Pneumonia module for high-risk patients requiring C	CrCU admission		
	🖄 Admit To	Service: Medicine, Regular Bed, Patient Diagnosis: Community Acquired Pneumonia, Internist on call until 0800		
⊿ Resus	⊿ Resuscitation Status			
	🖄 Resuscitation Status	Pt/SDM Resus Decision: FULL Resuscitation		

Prophylaxis and Proactive Care:

Proph	ylac	tic Measures
瀫	- (3)	P For inpatients with CAP, VTE prophylaxis should be used
	- 9 <u>-</u>	VTE Prophylaxis: Medical Condition (Adult) (Module)
瀫	- 🏈	For patients with community-acquired pneumonia (CAP) who smoke, consider smoking cessation therapy
	- 🏈	Smoking cessation interventions (eg, counseling, medications) should be given to smokers
	9.	Smoking Cessation (Adult & Adolescent) (Module)
DUC I		



Pneumonia Admission Order Set: Evidence-Based Empiric Antibiotic Treatment Selection

	Remi	nders						
1	瀫		Please refer to NYGH Antimicrobial Guideline Handbook, and select appropriate emp	piric antimicrobial regimens during first 24 hours. Use oral option when possible				
			unless NPO or vomiting					
	3	٩	Antibiotics should be administered as soon as possible (within 4-6 hours) after the di last 3 months for any reason, select an antibiotic from an ALTERNATE class	agnosis of CAP has been made in ER. If patient has taken an antibiotic within the				
+	1	18	EARLY SWITCH FROM PARENTERAL TO ORAL ANTIMICROBIAL THERAPY: should be	a considered followed by discharge for eligible patients (e.g. hernedynamically				
	1325	V	stable, improving clinically, normal GI tract, and able to ingest medications)	e considered followed by discharge for englishe patients (e.g. herhodynamically				
		- 🏈	For suspected aspiration OR Healthcare Associated Pneumonia (HCAP): Use the follo	owing modules instead of the antimicrobial options below				
		- <mark>9</mark> .	Pneumonia With Suspected Aspiration (Adult) (Modul					
		- <mark>9</mark> .	Pneumonia: Nosocomial/Health Care Associated Pne					
	謬 A	ntibio	tic Regimens					
	•	- 🏈	First-line treatment: Beta-lactam (ceftriaxone, or if taking PO, amoxicillin-clavulanic	acid). Addition of a macrolide is indicated for patients with severe illness, positive				
_			urine antigen, or suspected Legionellosis (See Atypical Coverage: Macrolide section I	below)				
		_ 🏈	In patients with a true beta-lactam allergy (eq. anaphylaxis, angioedema, or broncho	spasm): Respiratory fluoroquinolone alone				
	諸 諸 諸	_ 🏈	DURATION OF THERAPY: 5-7 days of therapy for hospitalized patients not in ICU					
	影日	rst lin	e Treatment: Beta-Lactam					
Ц	瀫	2	cefTRIAXone (Rocephin inj)	1000 mg, Inj, IV, q24h-ATC, NOW				
		2	amoxicillin-clavulanate (Clavulin F 875-125)	875 mg, PO, q12h, NOW				
		₫		500 mg, Tab, PO, q12h, NOW, Suggested dose for creatinine clearance 10-30 ml				
	Atypi	cal C	overage: Macrolide					
	_	_ ()	A macrolide for atypical coverage is indicated in patients with severe illness, positive	urine antigen, or suspected Legionellosis				
	33	2	azithromycin (Zithromax inj)	500 mg, Inj, IV, g24h-ATC, for 5 days, NOW				
	瀫	2	azithromycin (Zithromax)	500 mg, Tab, PO, q24h-ATC, NOW				
	謬B	eta-la	ctam Allergy: Quinolone					
		_ 🏈	A respiratory fluroquinolone is indicated in patients with a true beta-lactam allergy (eq. anaphylaxis, angioedema, or bronchospasm)				
		_ 🏈	Moxifloxacin (IV or PO) is indicated for low to intermediate risk patients					
	瀫	_ 💆	moxifloxacin (Avelox)	400 mg, Tab, PO, q24h-ATC, NOW				
	瀫	2	moxifloxacin (Avelox I.V.)	400 mg, Inj, IV, q24h-ATC, NOW				
			For renally impaired patients, no dose adjustment is required with moxifloxacin					
	Suspe	1.00	Pseudomonas					
			First-line treatment for SUSPECTED/PROVEN P.AERUGINOSA: piperacillin-tazobacta					
		٩	For patient with true beta-lactam allergy: Meropenem +/- azithromycin. Meropener	n is associated with low cross-reactivity among those with a beta-lactam allergy.				









Reminder

For patients who have atrial fibrillation and are at high or intermediate risk for stroke, use oral anticoagulation with apixaban, dabigatran, rivaroxaban, or warfarin.

For those who are unsuitable for warfarin therapy, use a direct thrombin inhibitor or factor Xa inhibitor.

For patients who have atrial fibrillation of ≥ 48 hours' duration or of unknown duration and who are undergoing cardioversion, use warfarin, an LMWH, apixaban, rivaroxaban, or dabigatran for at least 3 weeks prior to and 4 weeks after non-TEE-guide

For those who have atrial fibrillation of < 48 hours' duration and are undergoing cardioversion, use heparin (either IV UFH or an LMWH), a direct thrombin inhibitor, or factor Xa inhibitor if the patient is not already anticoagulated.

For patients with atrial fibrillation who have a creatinine clearance < 25 mL/minute, do not use apixaban.

For patients with atrial fibrillation who have a creatinine clearance < 15 mL/minute, do not use rivaroxaban.

Abbreviations | Guidelines

Rationale

The following table summarizes meta-analyses related to this topic:

Study	Comparison	
Giugliano et al (ENGAGE AF-TIMI 48, 2014)	High-dose (60 mg once daily) edoxaban vs Low-dose (30 mg once daily) edoxaban vs Warfarin	In patients with atrial fibrillation who have moderate-high stroke risk:
		 High-dose edoxaban decreases stroke (ischemic or hemorrhagic) during tr There is no significant between-group difference in stroke during treatment There is no significant between-group difference in a combined outcome o Low-dose edoxaban increases the frequency of a combined outcome of is Both high-dose and low-dose edoxaban decrease hemorrhagic stroke and
Halperin et al (ROCKET AF, 2014)	Rivaroxaban vs Warfarin	In patients with nonvalvular atrial fibrillation at moderate to high risk of stroke:
		 In patients ≥ 75 years of age:
		 Rivaroxaban increases the combined outcome of major or clinically There is no significant between-group difference in a combined outc
		 In patients < 75 years of age:
		 There is no significant between-group difference in a combined outc There is no significant between-group difference in a combined outc
Lip et al (2014)	Apixaban vs Aspirin	Based on data from the AVERROES study and at a mean follow-up of 1.1 years,
		 In all patients, apixaban decreases ischemic stroke. In female patients, apixaban decreases ischemic stroke. In male patients, apixaban decreases ischemic stroke. In all patients, there is no significant between-group difference in intracrani In female patients, there is no significant between-group difference in intracrani In male patients, there is no significant between-group difference in intracrani
Hylek et al (2014)	Apixaban vs Warfarin	Based on data from the ARISTOTLE trial, in patients with atrial fibrillation, apixab
Artang et al (2013)	Warfarin vs Alternative anticoagulant (eg, direct thrombin inhibitors, factor Xa inhibitors, aspirin, clopidogrel)	In patients with atrial fibrillation, there is no significant between-group difference in
Bruins Slot and Berge (CD008980, 2013)	Factor Xa inhibitors vs Vitamin K antagonists	In patients with atrial fibrillation or atrial flutter, factor Xa inhibitors reduce the com strokes, major bleedings, intracranial hemorrhages, and all-cause deaths.

Integrating New Evidence

- 6.25 mg Tab PO q12h Instructions: Give with food to minimize risk of orthostatic hypotension. Hold if HR < 55 bpm, Hold if SBP < 95 mmHg,</p>
- 12.5 mg Tab PO q12h Instructions: Give with food to minimize risk of orthostatic hypotension. Hold if HR < 55 bpm, Hold if SBP < 95 mmHg,</p>
- 25 mg Tab PO q12h Instructions: (target dose FOR WEIGHT </= 85 KG) Give with food to minimize risk of orthostatic hypotension. Hold if HR < 55 bpm, Hold if SBP < 95 mmHg,</p>
- 50 mg Tab PO q12h Instructions: (target dose FOR WEIGHT > 85 KG) Give with food to minimize risk of orthostatic hypotension. Hold if HR < 55 bpm, Hold if SBP < 95 mmHg,</p>

ARBs (Angiotensin Receptor Blockers)

- AREDUCED EF (HF-REF): Angiotensin-II receptor blockers (ARBs) are recommended in ACEI-intolerant patients, to reduce morbidity and mortality. Routine combination of ACE-I, ARB, and aldosterone antagonist therapy is potentially harmfu
- BRESERVED EF (HF-PEF): ARBs may be considered in patients with hypertension, or to decrease hospitalization for patients with heart failure and PEF

Atacand (C
-----------	---

- 4 mg Tab PO daily Hold if SBP < 95 mmHg,</p>
- 8 mg Tab PO daily Hold if SBP < 95 mmHg,</p>
- 16 mg Tab PO daily Hold if SBP < 95 mmHg,</p>
- 32 mg Tab PO daily Instructions: (target dose) Hold if SBP < 95 mmHg,</p>

Diovan 🖸

- 40 mg Tab PO q12h Hold if SBP < 95 mmHg,</p>
- 80 mg Tab PO q12h Hold if SBP < 95 mmHg,</p>
- 160 mg Tab PO q12h Instructions: (target dose) Hold if SBP < 95 mmHg,</p>



Pneumonia Admission Order Set: "Choosing Wisely": ordering investigations

Mic	robiolo	dA	
📓 🛛 🖗 Blood cultures are recommended for patients who meet 🕞 2 SIRS criteria or require admission to the CrCU (Ref: Quality-Based			
	Procedures Clinical Handbook for Community-Acquired Pneumonia, Nov 2013)		
🗆 🞲 🔀 Blood C&S #1 - Aerobic/ Anaerobic Priority: ASAP, Specimen Source: Bl		Priority: ASAP, Specimen Source: Blood Spe	
	_		Obtain prior to administering antibiotics
	2	Blood C&S #2 - Aerobic	Priority: ASAP, Specimen Source: Blood Spe
			Obtain prior to administering antibiotics
口 謬	2	Respiratory Culture & Sensitivity (Sputum Culture & S	Priority: Routine, Specimen Source: Sputum
	Ż	TB Culture - PHL (Sputum for AFB)	Priority: Routine, Specimen Source: Sputum Day 1 on Admission
	7	TB Culture - PHL (Sputum for AFB)	Priority: Routine, Specimen Source: Sputum
	_		Day 2 of Admission
	Ø	TB Culture - PHL (Sputum for AFB)	Priority: Routine, Specimen Source: Sputum
(HE)	18.	Consider testing for Legionella Urine Antigen for patients with severe pneumonia, pa	tients not responding to drug therapy after
1	- 🍼		
		48-72 hours, and inpatients during peak season (mid-June to early October)	
	Ø	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL	Priority: Routine
口 謬		48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL mology	Priority: Routine
		48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL	Priority: Routine
口 謬	Diogy/V �	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL protogy Consider influenza testing for selected patients, only if it will influence clinical manage	Priority: Routine
口 謬 Sen 謬	ت المراجعة في ت	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL protogy Consider influenza testing for selected patients, only if it will influence clinical manage See evidence link	Priority: Routine gement. PCR is more sensitive than viral culture.
□ 瀫 serc 溕 □ 瀫 ⊿ Diac	ک مالومیں ک ک مnostic	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL protogy Consider influenza testing for selected patients, only if it will influence clinical manages See evidence link Influenza	Priority: Routine gement. PCR is more sensitive than viral culture.
□ 瀫 serc 溕 □ 瀫 ⊿ Diac	Diogy/V Siogy/V (© anostic neral Ra	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL motogy Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph
□ 蒙 serc 蒙 □ 蒙 △ Diag Gen	Diody/ V Sinody/ Sinody/ Sinod	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL rotogy Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging diology For patients with physical findings or history suggestive of CAP, perform posteroante	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph erior and lateral chest radiography for diagnosis
□ 蒙 Set 3 2 Diac Gen 蒙	Diogy/V Shogy/V Onostic heral Ra	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL TOTOGY Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging diology For patients with physical findings or history suggestive of CAP, perform posteroante and evaluation For CAP patients who had only AP CXR consider ordering follow up PA/L CXR partice	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph erior and lateral chest radiography for diagnosis
□ ਡੋ Sero ਡੋ 4 Diac Gen ਡੋ ਡੋ	Diogy/V Shogy/V Onostic heral Ra	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL TOTOGY Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging diology For patients with physical findings or history suggestive of CAP, perform posteroante and evaluation For CAP patients who had only AP CXR consider ordering follow up PA/L CXR partice Pneumonias	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph erior and lateral chest radiography for diagnosis ularly for those patients who have Lower Lobe
□ ਡੋ Sero ਡੋ 4 Diac Gen ਡੋ ਡੋ	Diody/ V Scan	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL TOTOGY Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging diology For patients with physical findings or history suggestive of CAP, perform posteroante and evaluation For CAP patients who had only AP CXR consider ordering follow up PA/L CXR partice Pneumonias	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph erior and lateral chest radiography for diagnosis ularly for those patients who have Lower Lobe Reason: Suspected community-acquired pn
□ 38 sero 38 4 Diac Gen 38 23 24 0 38 38 38 38 38 38 38 38 38 38 38 38 38	الله المعرفين المعرفيين المعرفين المممموميمن الممممممان المعمموممامممممامي المممماممامممممامي الم	48-72 hours, and inpatients during peak season (mid-June to early October) Legionella Urine - PHL TOTOGY Consider influenza testing for selected patients, only if it will influence clinical managese evidence link Influenza Imaging diology For patients with physical findings or history suggestive of CAP, perform posteroante and evaluation For CAP patients who had only AP CXR consider ordering follow up PA/L CXR partice Pneumonias Chest PA / Lateral Although CXR is less sensitive than CT Chest for detecting pulmonary infiltrates, rout	Priority: Routine gement. PCR is more sensitive than viral culture. Priority: Routine, Specimen Source: Nasoph erior and lateral chest radiography for diagnosis ularly for those patients who have Lower Lobe Reason: Suspected community-acquired pn




Quality-Based Procedures Clinical Handbook for Community-Acquired Pneumonia

Health Quality Ontario & Ministry of Health and Long-Term Care November 2013

Ontario





"Launching CPOE will magnify existing workflow and policy problems in your organization"


Workflow Integration for CPOE

CPOE: "Strapping a new solution onto an old broken process can spell disaster!"



Workflow Integration for CPOE

CPOE implementation is a **key opportunity** to integrate evidence and best practices into new clinical workflows



Workflow Integration for CPOE

Integrating Workflows: Mobilizing Evidence with People and Technology

Re-engineer care processes to mobilize evidence:

- Stroke:
 - Bedside swallowing assessment
 - SCD's
- Prevention of VTE
- Prevention of IV contrast-induced nephropathy/renal failure
- Therapeutic drug monitoring (digoxin, aminoglycosides)





Making a World of Difference

Order Set Design: Strong Influence on Evidence-Based Care (example: Stroke)

Original Order Set:

- NPO diet order not mandatory
- Swallowing screen separate from diet, not mandatory

Revised Design:

- Swallowing screen mandatory
- Diet orders streamlined, integrated with swallowing
- Audit: 10-week period before and after revision:
 - Number of patients referred for screening doubled
 - Patients screened within 24hr increased from 81% to 96%

Diet
Patients with ischemic stroke should undergo a bedside swallowing screening test before taking foods, fluids, or medications by mouth. 2
Acute Stroke Swallowing Screen 🥛 💈
橘 Routine Reassess diet after swallowing screen (TOR-BSST). Please call 4 North x6388 for
NPO
VPO except medications
0
Change Diet
Nurse to advance diet as per the TOR-BSST guidelines (if patient passes swallowing screet)

Activity

Activity as Tolerated

🗹 Routine Nurse and/or team to advance mobilization as tolerated



What Were the Results? Selected Outcomes from NYGH eCare



TORONTO STAR

Metro Edition

Thursday Dec 13, 2012

In-Hospital Death Rates Down Across Greater Toronto Area

- Annual CIHI Report demonstrated that preventable in-hospital deaths were reduced
- NYGH top performer in Greater Toronto and second best in all of Canada
- CEO Tim Rutledge: "health information technology has hard-wired quality and safety into the hospital"





Making a World of Difference

HSMR:

- Reported from hospitals to CIHI annually
- Reported to public by CIHI annually
- GOAL: Reduce preventable inpatient deaths

Canadian Institute for Health Information
OurHealthSystem.ca



THIS TOOL CONTACT US FRANÇAIS




NYGH.ON.CA

SEE. KNOW. SHARE.

Hospital Deaths (HSMR)

This indicator of health care quality measures whether the number of deaths at a hospital is higher or lower than you would expect, based on the average experience of Canadian hospitals (set at 100 in 2009). When tracked over time, this measure can indicate whether hospitals have been successful in reducing patient deaths and improving care.



Case: Reducing Inpatient Mortality



Study: CPOE and Evidence-Based Order Sets

Retrospective chart review:

- All patients discharged with a main diagnosis of Pneumonia or COPD
 - **<u>Population #1</u>**: Pre-CPOE (Jan-Sep 2010) n = 520
 - Population #2: Post-CPOE (Jan-Sep 2011) n = 511
 - Groups similar in age, gender distribution
 - Corrections: "Probability of Death", critical care admission

Primary Hypothesis:

 Use of CPOE is associated with reduction in adjusted mortality vs traditional paper processes

Secondary Hypothesis:

• Use of CPOE with a matching evidence-based admission order set is associated with reduction in adjusted mortality vs use of any order set





Results: CPOE vs Paper

Making a World of Difference

Outcome	Odds Ratio	Confidence Interval	p-value
Death	0.574	0.391 – 0.843	0.005
Death adj for Probability of Death	0.571	0.383 – 0.852	0.006
Death adj for Probability of Death and CrCU Admission	0.547	0.360 – 0.830	0.005
30-Day Readmission	0.835	0.573 – 1.210	0.345
30-Day Readmission adj for Probability of Death and CrCU Admission	0.837	0.562 – 1.250	0.380

Case: Reducing Inpatient Mortality



Making a World of Difference

Results: Evidence-Based Order Set Selection

Order Set	Outcome	Odds Ratio	Confidence Interval	p- value
Diagnosis-appropriate	Death	0.48	0.26 - 0.90	0.022
Diagnosis-appropriate	Death adj for Probability of Death and CrCU Admission	0.44	0.21 - 0.90	0.024
Diagnosis-appropriate	30-Day Readmission	1.35	0.75 – 2.38	0.30
Close to diagnosis	Death	1.47	0.71 - 3.01	0.30
Close to diagnosis	Death adj for Probability of Death and CrCU Admission	1.82	0.78 – 4.23	0.16
Any order set	Death	0.55	0.12 – 2.54	0.44
Any order set	30-Day Readmission	1.53	0.19 – 11.92	0.69

Case: Reducing Inpatient Mortality



Making a World of Difference

Results: Adoption and Culture Change


	Paper Orders		CPOE (eCare)	
Percentage of patients for whom a diagnosis-	Pneumonia	26.05%	Pneumonia	60.43%
appropriate order set was used	COPD	0.0%	COPD	45.1%
Percentage of patients for whom any admission	Pneumonia	37.90%	Pneumonia	97.54%
order set was used	COPD	35.11%	COPD	97.35%



of Difference

Inpatient Preventable Mortality: Trended Format

HSMR – Medicine Program



1 – eCare Phase 2 Implementation (CPOE, order sets, electronic med management) 2 – Quality Based Procedure (QBP) implementation – phased, over 1 year

Case: Reducing Inpatient Mortality



Making a World of Difference

Making Quality Stick: VTE Prophylaxis

% Appropriate VTE Prophylaxis 97 100 96 90 84 80 65 70 60 50 50 40 30 17 20 10

0 2007 2007 2010 2012 2010 2016 (GEERTS ET (PAPER VTE (PRE-CPOE) (POST-CPOE (POST-CPOE (IMPROVED AL) **ORDER SET)** NO ALERT) WITH ALERT) ALERT)

Case: Venous Thromboembolism Prophylaxis

MEDREC: NYGH MEDICINE PROGRAM Best Possible Med History Admission Med Rec Discharge Med Rec 100.00% 90.00% 80.00% 70.00% 60.00% **Post-CPOE:** 45% admit, 50.00% 70% discharge 40.00% 30.00% 20.00% **Pre-CPOE:** 7 to 9% avg 10.00% 0.00% 589-10 Mat In I In And Service I was been and

Case: Medication Reconciliation



of Difference

Clinical Decision Support to improve Admission Medication Reconciliation

NYGH.ON.CA


Alert to remind Most Responsible Physician (MRP)

- Best Possible Medication History is available

Discern: Open Chart - PMREIMER, Mr. JAMES
C Admission Med Rec Alert
Admission Medication Reconciliation has not been completed for PMREIMER, JAMES
Please perform Admission Medication Reconciliation as follows:
1) Select the Orders tab from the left-hand menu of the patient chart
2) Click the Reconciliation button, and choose "Admission" from the drop-down list
OK

Case #1: Medication Reconciliation


MEDREC: NYGH MEDICINE PROGRAM



Case: Medication Reconciliation

Overall Clinician Satisfaction

	Primary	Secondary	p	OR (95% CI)
In general, how satisfied are you overall with the CPOE system you are currently working with?	28/34 (82%)	25/29 (86%)	.677	.75 (.19 – 2.95)
(Satisfied + Very Satisfied responses)				
(Satisfied - very Satisfied responses)				





Summary of eCare Clinical Benefits

- **100%** clinician adoption
- MedRec improved from 8% to 90%, with significant reduction in pharmacist interventions for duplicate meds and omitted medications
- Medication turnaround time improved by 83% (291→50 mins), with prevention of 11,000 patient mismatch errors and reduction in reported medication adverse events
- Appropriate prophylaxis against VTE increased from 50% of inpatients to >97% of inpatients (with help of alerts), with a corresponding 39% reduction in VTE
- Order set usage for patient admission to hospital increased from 36.5% (paper) to >97% (CPOE), even though use not mandatory
- Mortality from pneumonia and COPD exacerbation was reduced by 45% using CPOE vs paper orders, and by 56% using CPOE with a correctly-matched evidence-based order set



eCare ROI Calculation

Canadian cost of adverse nosocomial events:

Cost per medication error: \$402 to \$632 (median \$517 CDN)
 Cost per nosocomial adverse drug event: \$4,028 CDN
 Cost per case of nosocomial VTE: \$24,41
 Cost per case f nosocomial view saved per cost of 31 lives save

MedicationCOPD exactorS0,428Adverse Drug EvePRICELESS\$31,002,1.9Discrepancy\$1,029,169VTE prevention\$293,376Prevented recurrences of C.difficile\$293,376TOTAL COST AVERTED\$38,115,113

→ Net savings over 5 years: \$1.2 million



Making a World of Difference

What is the "Secret Sauce"? Local Clinicians and Informaticians

Positive <u>**OR**</u> negative outcomes are possible using the <u>same vendor software</u>:

- Children's Hospital of Pittsburgh 2005: increased mortality
- North York General Hospital 2010-2015: decreased mortality

To obtain clinical and financial benefits from implementing advanced HIS, we need:

- Engagement of clinicians, in partnership with informaticians
- Careful review and redesign of clinical workflows and content for clinical transformation – "Make it easy to do the right thing"
- System adoption \rightarrow ownership \rightarrow stewardship



EHR the Canadian Way: Challenges and Advantages

Are we making progress?

United States EMR Adoption ModelSM

Canada EMR Adoption ModelSM

STAGE	2017 Q1	2017 Q2	STAGE	2017 Q1	2017 Q2
7	5.0%	5.3%	7	0.2%	0.3%
6	31.9%	32.4%	6	1.2%	1.1%
5	34.3%	34.1%	5	3.9%	3.9%
4	10.0%	9.8%	4	1.4%	1.6%
3	13.3%	13.1%	3	30.6%	30.6%
2	1.9%	1.9%	2	29.6%	29.5%
1	1.6%	1.6%	1	15.6%	15.5%
0	1.9%	1.8%	0	17.6%	17.5%
	N:5,479	N:5,478		N:643	N:644

 Progression to HIMSS EMRAM Stage 4 and above is associated with improved care: quality, safety and value

- Amarasingham R et al. Arch Intern Med 2009 169(2):108-14

- 2006 HIMSS EMR Sophistication Correlates to Hospital Quality Data - 2012 HIMSS Analytics Report: Quality and Safety

NYGH.ON.CA

US has 12x the proportion of sites at HIMSS Stage 4 and above vs Canada (81.6% vs 6.9%)

Canadian Challenges

- Funding
- No central program of financial bonuses/penalties
- No clinically-focused maturity models in use
- Insufficient regulatory enforcement of terminology standards
- American Hospital Information System vendors:
 - Architected to meet American regulatory requirements, clinical workflows
 - Vendor clinical content focused on American standards, units of measure
 - Custom work required to accommodate / integrate Canadian provincial standards, systems, regulatory requirements, reporting
- Disparate constellation of primary care / long-term care systems, certification requirements differ from hospital sector
- Many healthcare organizations independently managed/operated (only some co-ordinated regional health systems, developing cross-sector "ACO's")



Making a World of Difference

Canadian Advantages

- Healthcare System Integration:
 - Regional Health Authorities, Cross-Continuum Management / Care
 - Centralized Health Information Systems are developing
- Publicly Funded Healthcare System:
 - Organizations co-operate rather than compete
 - → Open for Sharing



Our path to smarter, seamless care

Health



ConnectingOntario



Making a World of Difference



CPOE TOOLKIT: BY THE NUMBERS

www.cpoe-toolkit.ca



contributing organizations










1,544 evidence-based order sets

Ontario HIS Benefits and Adoption Team (HISBAT)

- Led by North York General Hospital (HIMSS 6) and Ontario Shores Centre for Mental Health Sciences (HIMSS 7), both Davies Enterprise Award winners
- Peer-to-peer knowledge sharing, mentorship of HIS project teams through on-site visits
- Provided at no cost to Ontario hospitals
- First 9 months 50+ hospitals assisted



Ontario HIS Renewal Strategy



Ontario's approach to HIS renewal focuses on accelerating maturity in three key areas that are all critical to success:

- HIS Clustering
- HIS Service Delivery
- Clinical Adoption & Outcomes

Implementation will be supported by key policy enablers:


- Funding
- Procurement

HIS Renewal Panel Recommendations:


Significantly changing the landscape of HIS procurement, funding, and partnerships

HIS Renewal Maturity Path

• Optimizing the benefits from HIS investments will depend on advancing maturity in the three key areas in tandem.



Provincial Schematic – Clinical Standardization





Success: the Canadian Way



Share globally:

- Lessons learned
- Best Practices
- Clinical Content
- Standards
- Patient data (cross-continuum)

Act locally:

Clinicians + Informaticians + Vendors





NORTH YORK GENERAL

Making a World of Difference

THANK YOU!

For more information please contact:

Jeremy Theal, Chief Medical Information Officer Jeremy.Theal@nygh.on.ca

Twitter: @drjeremytheal